Why the price has increased today

  • The Plus Therapeutics Inc (NASDAQ: PSTV) share price rose more than 19% during today’s intraday trading. That’s why it happened.

The share price of Plus Therapeutics Inc (NASDAQ: PSTV) – a clinical-stage pharmaceutical company that develops innovative, targeted radiation therapy products for rare and difficult-to-treat cancers – rose more than 19% in trade. intraday today. Investors are responding positively to Plus Therapeutics by announcing that it has entered into an agreement with the University of Texas at San Antonio Health Sciences Center (UT Health San Antonio) for an exclusive worldwide license to develop and commercialize new interventional cancer therapies.

The licensed patents include the Composition of Matter Patents for Biodegradable Alginate Microspheres (BAMs) containing nanoliposomes loaded with imaging and / or therapeutic payloads. And therapeutic payloads can include radiotherapeutics, chemotherapeutics, or thermotherapeutics. BAM technology is introduced into the vascular system via standard interventional vascular catheters that are placed precisely in the vessels supplying tumors. Once injected, BAM blocks all blood flow to tumors and simultaneously delivers very high doses of cytotoxic compounds over an extended period of time. And several days later, the BAM resolves and is physiologically metabolized and excreted from the body.

The financial terms of the exclusive license agreement are primarily success-based, with milestone and royalty payments contingent upon the achievement of key clinical, regulatory and commercial milestones.

And the company will focus on the development first 188RNL-BAM as a next-generation radioembolization therapy for liver cancer, in which BAM blocks the segments of the hepatic artery that supply blood to the malignant tumor while providing 188RNL radiotherapy by directly irradiating the tumor.

Liver cancer is known as a rare disease with an increasing annual incidence and an overall 5-year survival of only 20%. And the global opportunity for localized embolization, chemoembolization and radioembolization therapies for primary (hepatocellular carcinoma) and secondary (typically metastatic colorectal cancer, for example) liver cancer is $ 1.3 billion.

The initial inventions and the work behind the patents and licensed technologies were developed and led by William Phillips MD, professor of nuclear medicine, Ryan Bitar, MD, and their team at UT Health San Antonio. the 188RNL-BAM technology incorporates rhenium-188, or 188Re, a very attractive isotope for use in radiotherapeutic embolization due to its high energy electron emission (beta particle) with a half-life of 16.9 hours and a path length of 3.1 mm. 188Re emits gamma energy that enables high-quality real-time imaging of the location and confirmation of delivery of the BAM construction.

And 188RNL-BAM is simple and economical to manufacture for on-demand availability for therapeutic applications and is versatile and can be precisely composed and fabricated to a specific size allowing optimal arterial embolization to block blood flow in most beds vascular cells while simultaneously delivering its payload isotope to the tumor. BAMs are not permanent like other technologies and degrade over time, allowing the restoration of blood flow, decreasing resistance to radiation and allowing physiological and safe elimination of 188Re through the kidneys, which avoids the toxicity of the bone marrow.

KEY QUOTES:

“The future of cancer therapy lies in the precise targeting of tumors with the most potent anti-cancer agents while minimizing damage to normal tissue. This important transaction not only further expands our existing Rhenium NanoLiposome technology, but it also helps to realize that future. With this technology, we can target almost any solid organ tumor in the body using standard interventional means to take advantage of the expanse of the human vasculature and provide resorbable biomaterial embolic technology coupled to a radiotherapeutic isotope. very powerful.

– Marc H. Hedrick, MD, President and CEO of Plus Therapeutics

“Embolization technology for many types of tumors, including liver cancer, has been used with promising results for more than two decades, but significant limitations remain and no significant recent technological innovation has been achieved. The major radioembolization therapies available today incorporate Yttrium-90 glass / resin microspheres which have poor imaging characteristics, require long delays, are permanently implanted, and can expose the marrow to high levels of radiation. Rhenium-188 Biodegradable Alginate Microsphere NanoLiposome (188RNL-BAM) is a new generation fully absorbable technology that solves many problems of existing technology. Our team at UT Health San Antonio intends to help Plus Therapeutics bring this technology to market quickly. “

– William Phillips, MD, professor of nuclear medicine at UT Health San Antonio

“This transaction is the next step in our plan to expand our pipeline using precision targeted radiation therapy. The next steps are to complete and compile the promising preclinical work done so far and to prepare an IND submission in 2022 for the treatment of liver cancer.

– Norman LaFrance, MD, Medical Director of Plus Therapeutics

Disclaimer: This content is intended for informational purposes. Before you make an investment, you need to do your own analysis.


Source link